Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Bristol Myers Squibb Drug Patent Portfolio

Bristol Myers Squibb's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Bristol Myers Squibb:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) Karuna Therapeutics, Inc., a Bristol Myers Squibb company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents Karuna Therapeutics, Inc., a Bristol Myers Squibb company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) Karuna Therapeutics, Inc., a Bristol Myers Squibb company NA RECRUITING
(Aug 1, 2026)
PHASE3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia Karuna Therapeutics, Inc., a Bristol Myers Squibb company NA COMPLETED
(Jul 1, 2026)
PHASE3
A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin Karuna Therapeutics, Inc., a Bristol Myers Squibb company NA COMPLETED
(Jul 1, 2026)
PHASE1
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) Karuna Therapeutics, Inc., a Bristol Myers Squibb company NA RECRUITING
(Jun 1, 2026)
PHASE3
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia Karuna Therapeutics, Inc., a Bristol Myers Squibb company NA COMPLETED
(Apr 1, 2026)
PHASE3


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Bristol Myers Squibb News

Pharmalittle: Promising pancreatic cancer findings, Replimune medication not approved - STAT News

13 Apr, 2026

Bristol Myers Squibb's stock (US1101221083): Does its cancer treatment pipeline have the potential to drive growth?

10 Apr, 2026

Could Positive Camzyos Results Enhance BMY's Cardiovascular Offerings? - Yahoo Finance

30 Mar, 2026

Could the Recent Label Expansion of BMY's Opdivo Enhance Its Immuno-Oncology Portfolio? - TradingView

25 Mar, 2026

See More